ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR121

A Global Anti B-Cell Strategy with Obinutuzumab and Daratunumab in Severe Pediatric Idiopathic Nephrotic Syndrome

Session Information

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology


  • Dossier, Claire, APHP, Robert-Debre Hospital, Paris, France
  • Prim, Benjamin, APHP, Robert-Debre Hospital, Paris, France
  • Moreau, Christelle, APHP, Robert-Debre Hospital, Paris, France
  • Kwon, Theresa, APHP, Robert-Debre Hospital, Paris, France
  • Couderc, Anne, APHP, Robert-Debre Hospital, Paris, France
  • Alexandra, Cambier, APHP, Robert-Debre Hospital, Paris, France
  • Baudouin, Veronique, APHP, Robert-Debre Hospital, Paris, France
  • Maisin, Anne Francoise, APHP, Robert-Debre Hospital, Paris, France
  • Deschênes, Georges, Hospital Robert Debre/Pediatric Nephrology, Paris, France

The efficacity of B-cell depletion and Immunoglobulin adsorption in the treatment of patients with Steroid Dependant Nephrotic Syndrome (SDNS) and Steroid Resistant NS supports the involvement of B cells in the physiopathology of INS. However, rituximab (RTX) targets only CD20 positive B-cells and especially not plasma cells. Furthermore, RTX mediated B-cell depletion may paradoxically induce the settlement of autoreactive long-lived plasma cells which may account for some RTX failure. In this pilot study, we investigate in patients with severe SDNS the association of Obinutuzumab (OBZ), a 2ndgeneration anti CD20 monoclonal antibody, with higher in vitro B-cell cytotoxicity than RTX, with Daratumumab (DAR), an anti CD38 monoclonal antibody with high plasma cell cytotoxicity in addition to an immunomodulatory activity.


Patients received an infusion of 1000mg/1,73m2 of obinutuzumab at day 0 and 1000mg/1,73m2 of daratumumab at day 15. All other immunosuppressive treatments were discontinued within two months, and biological monitoring was performed monthly until B cell recovery.


9 patients with SDNS and resistance (n=3) or early relapse after prolonged B-cell depletion with rituximab (n=6) were included. Median ages at INS onset, first RTX and OBZ were respectively of 2.9, 7.7 and 10.9 years old. B-cell depletion was achieved in all patients. Median follow-up was 10 months (IQ 8.3-10.3), and all patients remained relapse-free. Six patients had still undetectable peripheral B-cells, while B-cell reconstitution occured at 7.9, 8.1 and 9.3 months in the 3 others. Mild infusion reactions were reported in 2/9 patient during OBZ and 3/9 during DAR infusions. Mild neutropenia (500-1000/mm3) occured in 2/9 patients. 7/9 patients received IV immunoglobulins because of hypo-IgG. Hypo-IgA was noted in 8 patients and hypo-IgM in all patients. No severe infection was reported.


Global anti-B cell strategy with obinutuzumab and daratumumab induces prolonged peripheral B-cell depletion and nephrotic syndrome remission in children with severe SDNS. However, it induces frequent and profound hypogammaglobulinemia and further investigation of the safety and the long-term efficacy of this strategy is needed.